Vehreschild, Maria J. G. T., Weitershagen, David, Biehl, Lena M., Tacke, Daniela, Waldschmidt, Dirk, Toex, Ulrich, Wisplinghoff, Hilmar, Bergwelt-Baildon, Michael V., Cornely, Oliver A. and Vehreschild, Joerg J. (2014). Clostridium Difficile Infection in Patients with Acute Myelogenous Leukemia and in Patients Undergoing Allogeneic Stem Cell Transplantation: Epidemiology and Risk Factor Analysis. Biol. Blood Marrow Transplant., 20 (6). S. 823 - 829. NEW YORK: ELSEVIER SCIENCE INC. ISSN 1523-6536

Full text not available from this repository.

Abstract

Patients receiving treatment for acute myelogenous leukemia (AML) and recipients of allogeneic stem cell transplantation (aSCT) are at high risk of contracting Clostridium difficile infection (CDI), the most frequently observed nosocomial diarrhea and enterocolitis. Data were retrieved from the prospective Cologne Cohort of Neutropenic Patients. Patients hospitalized for aSCT as well as patients receiving treatment for AML were included in the analysis. Risk factor analysis for the occurrence of CDI was performed by backward-stepwise logistic regression (P < .1). During the period from January 2007 to August 2010, 310 hospitalizations of 152 patients with AML and 229 hospitalizations of 223 patients undergoing aSCT were eligible for analysis. Incidence rates for CDI per 10,000 patient days were 17.9 for AML patients and 27.4 for aSCT recipients. Among AML and aSCT patients, median time from initiation of chemotherapy to CDI was 10 days (range, -8 to 101 days) and 17 days (range, 6 to 79), respectively. Logistic regression identified carbapenem exposure to be associated with development of CDI in AML patients (odds ratio [OR], 2.2) and aSCT recipients (OR, 1.4). In both groups, previous exposure to carbapenems was significantly associated with development of CDI. A follow-up study, assessing the effect of an antibiotic stewardship intervention to decrease the administration Of carbapenems in hematological high-risk patients, is warranted. (C) 2014 American Society for Blood and Marrow Transplantation.

Item Type: Journal Article
Creators:
CreatorsEmailORCIDORCID Put Code
Vehreschild, Maria J. G. T.UNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Weitershagen, DavidUNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Biehl, Lena M.UNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Tacke, DanielaUNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Waldschmidt, DirkUNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Toex, UlrichUNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Wisplinghoff, HilmarUNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Bergwelt-Baildon, Michael V.UNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Cornely, Oliver A.UNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Vehreschild, Joerg J.UNSPECIFIEDUNSPECIFIEDUNSPECIFIED
URN: urn:nbn:de:hbz:38-437149
DOI: 10.1016/j.bbmt.2014.02.022
Journal or Publication Title: Biol. Blood Marrow Transplant.
Volume: 20
Number: 6
Page Range: S. 823 - 829
Date: 2014
Publisher: ELSEVIER SCIENCE INC
Place of Publication: NEW YORK
ISSN: 1523-6536
Language: English
Faculty: Unspecified
Divisions: Unspecified
Subjects: no entry
Uncontrolled Keywords:
KeywordsLanguage
DISEASES SOCIETY; BONE-MARROW; 2010 UPDATE; RECIPIENTS; NEUTROPENIA; AMERICA; MICROBIOLOGY; METAANALYSIS; GUIDELINES; MORTALITYMultiple languages
Hematology; Immunology; TransplantationMultiple languages
URI: http://kups.ub.uni-koeln.de/id/eprint/43714

Downloads

Downloads per month over past year

Altmetric

Export

Actions (login required)

View Item View Item